Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine
- 1 February 2007
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 44 (2) , 148-153
- https://doi.org/10.1097/qai.0b013e31802b920e
Abstract
Single-dose nevirapine (sd-NVP) is the mainstay of prevention of mother-to-child transmission programs in developing countries. Exposure to sd-NVP selects for resistance mutations, however. We longitudinally assessed these mutations in HIV-1-infected infants from Soweto and Durban, South Africa. We prospectively followed 465 infants who received sd-NVP after enrolling their mothers when pregnant. If HIV infected, their virus was genotyped, using the ViroSeq HIV-1 Genotyping System, to detect resistant mutations. Those with resistance were genotyped at 6 months and then every 6 months out to 18 months if resistance was detected at the previous visit. Of 53 HIV-infected infants, 24 (45.3%) had detectable resistance at their first visit, when the most frequent mutations were Y181C (75%), K103N (25%), and Y188C (12%). Of those whose visit was before 12 weeks of age, 2 of 42 infants shared identical resistance mutations with their mothers. By 18 months of age, 11 of 24 infants with resistance had died and 1 still had the Y181C mutation. Resistant mutations were selected in half of the infants exposed to sd-NVP, but fewer were detected over time and, unlike the case in their mothers, Y181C dominated initially and persists. Transient resistance mutations may have a negative impact on highly active antiretroviral therapy in infants and children.Keywords
This publication has 18 references indexed in Scilit:
- Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newbornsAIDS, 2005
- Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysisThe Lancet, 2004
- Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or DAIDS, 2004
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in ThailandNew England Journal of Medicine, 2004
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialThe Lancet, 2003
- In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variantsJournal of General Virology, 2002
- Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)AIDS, 2001
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- Predictors of Survival in Children with Acquired Immunodeficiency Syndrome in Italy, 1983 to 1995AIDS Patient Care and STDs, 1998